Key facts
- It has raised $20.3M across 1 recorded rounds; the latest was Seed Round ($506K) in Mar 2025.
- Notable investors include Investible, Brandon Capital, Aviron Investments, Oncology Ventures.
- Lumonus has filed 1 Form D with the SEC, most recently Mar 2025 ($506K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Lumonus
Funding rounds
1 roundsAbout Lumonus
Developer of a user-centric software designed to empower oncology care teams through AI-powered workflows. The company offers intelligent automation for physicians, treatment planning reimagined, and a learning health system, enabling healthcare providers to enhance efficiency, quality, and patient care.
- Sector
- Healthcare
- HQ
- Sydney, Australia
- Founded
- 2023
- Employees
- 62
- Website
- lumonus.com/
- Ownership
- Privately Held (backing)
Lumonus doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lumonus shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lumonus in its N-PORT filings yet. We sweep new filings monthly.